Michael Heffernan
Founder at COLLEGIUM PHARMACEUTICAL, INC.
Net worth: 2 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Wotton | M | 63 |
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | 7 years |
| Gregory Bailey | M | 68 | 10 years | |
| Jennifer Good | F | 59 | 13 years | |
| Michael Rogers | M | 64 | 8 years | |
| Julia Gregory | F | 71 | 7 years | |
| Vladimir Coric | M | 53 | 9 years | |
| John Childs | M | 81 | 10 years | |
| Ed Mathers Mathers | M | 64 | 12 years | |
| Peter Barrett | M | 71 |
Indalo Therapeutics, Inc.
 Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | 7 years |
| Irina Antonijevic | M | 59 | 2 years | |
| Steven Gilman | M | 71 | 8 years | |
| Robert Hugin | M | 69 | 4 years | |
| Joseph Ciaffoni | M | 53 | 7 years | |
| Antoine Awad | M | 44 | 6 years | |
| George Clark | M | - | 5 years | |
| Kimberly Gentile | F | 56 | 9 years | |
| Douglas G. Gray | M | - | - | |
| Garen Bohlin | M | 76 |
PreCision Dermatology, Inc.
 PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 12 years |
| Douglas R. Carlson | M | 45 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | 2 years |
| Terrence Connolly | M | - |
K36 Therapeutics, Inc.
 K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | - |
| Shirley Kuhlmann | F | 40 | 6 years | |
| Kishan Mehta | M | 38 | 3 years | |
| Mary Dooley | F | 43 | 6 years | |
| Matthew Buten | M | 62 | 3 years | |
| Rita Balice-Gordon | M | 63 | 4 years | |
| Scott Sudduth | M | - | 6 years | |
| John Freund | M | 70 | 10 years | |
| Scott Dreyer | M | 52 | 6 years | |
| Mark Hensley | M | - | 8 years | |
| Noel Barnard | M | - | 11 years | |
| Myles Wolf | M | 53 | 4 years | |
| Thomas Sciascia | M | 70 | 13 years | |
| Gwen Melincoff | M | 72 | 7 years | |
| Gino Santini | M | 66 | 12 years | |
| Jennifer Porcelli | F | - | 2 years | |
| Brendan St Amant | M | - | 3 years | |
| Irfan Qureshi | M | - | - | |
| Paloma Moraleda | F | - | 2 years | |
| Gastón Ortega | M | - | 2 years | |
| Terry Connolly | F | - |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | 3 years |
| Dominick Colangelo | M | 60 | 4 years | |
| Thomas J. Adam | M | - | 7 years | |
| John Fallon | M | 76 | 8 years | |
| Anne VanLent | F | 76 | 6 years | |
| Neil McFarlane | M | 51 | 2 years | |
| Thomas Holm Pedersen | M | - |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | 9 years |
| James Cassella | M | 69 | 4 years | |
| Richard Shea | M | 72 | 7 years | |
| Adrian Adams | M | 73 | 6 years | |
| Lori Kunkel | M | 66 |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | - |
| LeAnne M. Zumwalt | F | 65 | 3 years | |
| Megan M. Dow | M | - | 4 years | |
| Nick Leschly | M | 51 | 7 years | |
| Ronald Frieson | M | 65 | 3 years | |
| David Saunders | M | - | - | |
| Thomas J. O'Brien | M | 75 |
University of Connecticut
| 38 years |
| Katie McManus | F | - | - | |
| Josh Richardson | M | 42 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
| Jeremy Springhorn | M | 61 |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | 5 years |
| Clifford Bechtold | M | - | - | |
| Lisa Stocking | F | - | - | |
| Maryellen McQuade | F | - | - | |
| Rita L. Mannella | F | - | 7 years | |
| Morten Graugaard Døssing | M | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | - |
| Caroline Dircks | M | - | 4 years | |
| Ulf Meier-Kriesche | M | - | 7 years | |
| Sabine Dandiguian | F | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Craig Collard | M | 58 | 13 years | |
| Ira Duarte | F | 55 | 7 years | |
| Alastair Stuart McEwan | M | 69 | 3 years | |
| Michael Tarnok | M | 69 | 9 years | |
| Jodie Morrison | F | 48 | 4 years | |
| Mette Agger | F | 59 | 9 years | |
| Gary H. Rabin | M | 58 | 7 years | |
| Mark Enyedy | M | 60 | 4 years | |
| Johnny Stilou | M | 57 | 8 years | |
| Eran Nadav | M | 55 | 7 years | |
| Gregory Madison | M | 57 | 4 years | |
| Aoife Brennan | M | 48 | 8 years | |
| Jeffrey M. Nugent | M | 76 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 4 years |
| John D. Weinberg | M | 57 | 6 years | |
| Jason Amello | M | 55 | 7 years | |
| Elyse Stock | M | 66 | 5 years | |
| Edward Myles | M | 52 | 3 years | |
| Michael P. Culmo | M | - |
University of Connecticut
| 6 years |
| Masao Yoshida | M | - | - | |
| Scott A. Holmes | M | 50 | 3 years | |
| Declan Doogan | M | 72 | 8 years | |
| Jane C. I. Hirsh | F | - |
Onset Dermatologics LLC
 Onset Dermatologics LLC Pharmaceuticals: MajorHealth Technology Onset Dermatologics LLC develops and markets prescription product for skin disorders. The company was founded in 2005 and is headquartered in Cumberland, RI. | - |
| Patrick Heron | M | 53 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 8 years |
| David Spellman | M | 48 | 3 years | |
| Mark C. Boelhouwer | M | - |
University of Connecticut
| 2 years |
| Robert Repella | M | 65 | 2 years | |
| Enrico Picozza | M | 64 |
University of Connecticut
| 4 years |
| Eric Aguiar | M | 62 | 4 years | |
| James Engelhart | M | 60 | 5 years | |
| Charles Conway | M | 62 | 5 years | |
| John Tilton | M | 56 | 6 years | |
| David Durgin Wharmby | M | - |
University of Connecticut
| 17 years |
| Raimonds Dzelme | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 63 | 63.00% |
| Denmark | 15 | 15.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Heffernan
- Personal Network
